Study #2015-0921
Phase II Study of Inotuzumab Ozogamicin in Patients with B-cell Lineage Acute Lymphocytic Leukemia ;with Positive Minimal Residual Disease
Study Status
Open
Treatment Agent
Inotuzumab Ozogamicin
Principal Investigator
Elias Jabbour
Description
The goal of this clinical research study is to learn how well low-dose inotuzumab ozogamicin may help to control acute lymphocytic leukemia (ALL). The safety of the study drug will also be studied.
General Information
Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic
Treatment Agent: Inotuzumab Ozogamicin
Treatment Location: Only at MD Anderson
Sponsor: Pfizer, Inc. (Supporter)
Study Status
IRB Review and Approval Date: 02/15/2018
Recruitment Status: Open
Projected Accrual: N/A
Resources and Links
Information and next steps
Disease:
Malignant neoplasms stated as primary lymphoid haematopoietic
Study phase:
Phase II
Physician name:
Elias Jabbour
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789